Definium’s shares surge 55% after LSD-based depression pill delivers strong results

Definium Therapeutics said a single dose of its LSD-based experimental pill significantly reduced symptoms of major depression in patients in a late-stage trial, sending its shares soaring 55% to a more than four-year high on Monday. The experimental drug helped patients record significantly lower scores on a standard depression scale than those on placebo after six weeks,...